Latest News

Kedrion warns that a conflict in the Middle East could disrupt supplies of plasma to Iran

Kedrion, an Italian biopharmaceutical firm, said on Friday that it might struggle to deliver plasma-based medicine to patients in Iran if the disruption of shipping through 'the Strait of Hormuz' persists.

Ugo Di Francesco, the chief executive of the company, said that rising fuel costs could make logistics costs too expensive.

In an interview, Di Francesco said: "It is a matter of logistics. We need to be able to deliver products physically to patients."

He added, "So far we haven't experienced any significant impacts on our ability to ensure the availability of therapies."

Kedrion manufactures life-saving treatments for rare and ultrarare diseases. Its plasma collection system consists of 76 centres - 68 are in the U.S., and the rest are in the Czech Republic.

Permira is the company's controlling shareholder, with a 63.2% stake. The Italian Marcucci family holds 16.3% of the company, while Italian investment companies FSI and?CDP Equity are minor shareholders.

Kedrion and Britain's Bio Product Laboratory merged in 2022, creating a global group of plasma derivatives. Kedrion employs approximately 5,400 people.

The company reported revenue of 1.78 billion euros (?1.65 billion) in 2025. This is an increase of?4.5% from 2024. It also posted adjusted core earnings of 341.4 millions euros, which represents a 22.6% rise.

Di Francesco stated that the U.S. was responsible for 61% of their revenue last year. This share is expected to increase to 65% by 2026. (Editing by Gavin Jones & Mark Potter)

(source: Reuters)